Skip to main content
Top
Published in: Clinical Rheumatology 1/2005

01-02-2005 | Original Article

Validation of French version of the Scleroderma Health Assessment Questionnaire (SSc HAQ)

Authors: C. Georges, O. Chassany, L. Mouthon, K. Tiev, C. Toledano, O. Meyer, Z. Marjanovic, C. Heneggar, T. Papo, B. Crickx, D. Sereni, J. Cabane, D. Farge

Published in: Clinical Rheumatology | Issue 1/2005

Login to get access

Abstract

The modified Scleroderma Health Assessment Questionnaire (SSc HAQ) is a functional score to assess systemic sclerosis (SSc) comprising the HAQ disease index (HAQ-DI) plus five specific visual analogue scales (VAS). Since it was validated in English-speaking patients only, its general use in any other language necessitates prior cross-cultural adaptation and validation. We designed this study to assess its value in French-speaking patients and to validate the French version according to international recommendations. We elaborated a French version using the “forward-backward” method. We then validated its psychometric properties with 100 consecutive SSc French-speaking patients who had undergone simultaneous clinical and paraclinical examination. In addition, we calculated the SSc HAQ score, a new outcome measure, which is obtained by pooling the eight domains from the HAQ-DI with the five organ VAS. Our study confirmed the psychometric properties of the SSc HAQ in non-English-speaking patients with (a) structural validity: the major component analysis, performed on the HAQ-DI and the five VAS, yielding a two-factor structure; (b) convergent validity: with high correlation coefficients between the SSc HAQ score and the physical component score of the SF-36 (r=−0.74, p<0.0001); (c) discriminant validity: the SSc HAQ score was better in patients with limited than with diffuse SSc (0.5±0.5 vs 1.1±0.7, respectively, p<0.0001) in relation to the number of clinical involvements; (d) reproducibility was high using the test-retest procedure (r=0.98). This study showed the value of the SSc HAQ, which is a simple, discriminant, reproducible self-administered questionnaire to evaluate French-speaking SSc patients. In addition, we suggest the use of a new outcome measure, the SSc HAQ score, to assess this systemic disease more accurately.
Literature
1.
go back to reference Poole JL, Steno VD (1991) The use of the Health Assessment Questionnaire (HAQ) to determine physical disability in systemic sclerosis. Arthritis Care Res 4:27–31PubMedCrossRef Poole JL, Steno VD (1991) The use of the Health Assessment Questionnaire (HAQ) to determine physical disability in systemic sclerosis. Arthritis Care Res 4:27–31PubMedCrossRef
2.
go back to reference Steen VD, Medsger TA (1997) The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time. Arthritis Rheum 40:1984–1991PubMedCrossRef Steen VD, Medsger TA (1997) The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time. Arthritis Rheum 40:1984–1991PubMedCrossRef
3.
go back to reference Chassany O, Sagnier P, Marquis P, Fullerton S, Aaronson N, for the European Regulatory Issues on Quality of Life Assessment (ERIQA) group (2002) Patient-reported outcomes: the example of Health-Related Quality of Life—a European guidance document for the improved integration of health-related quality of life assessment in the drug approval process. Drug Inf J 36:209–238CrossRef Chassany O, Sagnier P, Marquis P, Fullerton S, Aaronson N, for the European Regulatory Issues on Quality of Life Assessment (ERIQA) group (2002) Patient-reported outcomes: the example of Health-Related Quality of Life—a European guidance document for the improved integration of health-related quality of life assessment in the drug approval process. Drug Inf J 36:209–238CrossRef
4.
go back to reference Gandek B, Ware JE Jr, Aaronson NK, Alonso J, Apolone G, Bjorner JB, et al. (1998) Tests of data quality, scaling assumptions, and reliability of the SF-36 in eleven countries: results from the IQOLA project. J Clin Epidemiol 51:1149–1158PubMedCrossRef Gandek B, Ware JE Jr, Aaronson NK, Alonso J, Apolone G, Bjorner JB, et al. (1998) Tests of data quality, scaling assumptions, and reliability of the SF-36 in eleven countries: results from the IQOLA project. J Clin Epidemiol 51:1149–1158PubMedCrossRef
5.
go back to reference Scientific Advisory Committee of the Medical Outcome Trust (2002) Assessing health status and quality of life instruments: attributes and review criteria. QOL Res 11:193–205 Scientific Advisory Committee of the Medical Outcome Trust (2002) Assessing health status and quality of life instruments: attributes and review criteria. QOL Res 11:193–205
6.
go back to reference LeRoy EC, Medsger TA Jr (2001) Criteria for the classification of early sclerosis. J Rheumatol 28:1573–1576PubMed LeRoy EC, Medsger TA Jr (2001) Criteria for the classification of early sclerosis. J Rheumatol 28:1573–1576PubMed
7.
go back to reference Fries JF, Spitz PW, Young DY (1982) The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. J Rheumatol 9:789–793PubMed Fries JF, Spitz PW, Young DY (1982) The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. J Rheumatol 9:789–793PubMed
8.
go back to reference Guillemin F, Briançon S, Pourel J (1991) Mesure de la capacité fonctionnelle dans la polyarthrite rhumatoïde: adaptation française du Health Assessment Questionnaire (HAQ). Rev Rhum 58:459–465PubMed Guillemin F, Briançon S, Pourel J (1991) Mesure de la capacité fonctionnelle dans la polyarthrite rhumatoïde: adaptation française du Health Assessment Questionnaire (HAQ). Rev Rhum 58:459–465PubMed
9.
go back to reference Acquadro C, Jambon B, Ellis D, Marquis P (1996) Language and translation issues. In: Spilker B (ed) Quality of life and pharmacoeconomics in clinical trials, 2nd edn. Lippincott-Raven, Philadelphia, pp 575–585 Acquadro C, Jambon B, Ellis D, Marquis P (1996) Language and translation issues. In: Spilker B (ed) Quality of life and pharmacoeconomics in clinical trials, 2nd edn. Lippincott-Raven, Philadelphia, pp 575–585
10.
go back to reference Ware JE Jr (1993) SF-36 Health Survey: manual and interpretation guide. Health Institute, New England Medical Center, Boston Ware JE Jr (1993) SF-36 Health Survey: manual and interpretation guide. Health Institute, New England Medical Center, Boston
11.
go back to reference Leplege A, Ecosse E, Verdier A, Perneger TV (1998) The French SF-36 Health Survey: translation, cultural adaptation and preliminary psychometric evaluation. J Clin Epidemiol 51:1013–1023PubMedCrossRef Leplege A, Ecosse E, Verdier A, Perneger TV (1998) The French SF-36 Health Survey: translation, cultural adaptation and preliminary psychometric evaluation. J Clin Epidemiol 51:1013–1023PubMedCrossRef
12.
go back to reference Medsger T, Silman A, Steen V, Black C, Akesson A, Bacon P, et al. (1999) A disease severity scale for systemic sclerosis: development and testing. J Rheumatol 26:2159–2167PubMed Medsger T, Silman A, Steen V, Black C, Akesson A, Bacon P, et al. (1999) A disease severity scale for systemic sclerosis: development and testing. J Rheumatol 26:2159–2167PubMed
13.
go back to reference Clements PH, Lachenbruch P, Siebold J, White B, Weiner S, Martin R, et al. (1995) Inter- and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 22:1281–1285PubMed Clements PH, Lachenbruch P, Siebold J, White B, Weiner S, Martin R, et al. (1995) Inter- and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 22:1281–1285PubMed
14.
go back to reference Lohr KN, Aaronson NK, Alonso J, Burnam MA, Patrick DL, Perrin EB, et al. (1996) Evaluating quality-of-life and health status instruments: development of scientific review criteria. Clin Ther 18:979–992PubMedCrossRef Lohr KN, Aaronson NK, Alonso J, Burnam MA, Patrick DL, Perrin EB, et al. (1996) Evaluating quality-of-life and health status instruments: development of scientific review criteria. Clin Ther 18:979–992PubMedCrossRef
15.
go back to reference Guyatt GH, Kirshner B, Jaeschke R (1992) Measuring health status: what are the necessary measurement properties? J Clin Epidemiol 45:1341–1345PubMedCrossRef Guyatt GH, Kirshner B, Jaeschke R (1992) Measuring health status: what are the necessary measurement properties? J Clin Epidemiol 45:1341–1345PubMedCrossRef
16.
go back to reference Chassany O, Marquis P, Scherrer B, Read NW, Finger T, Bergmann JF, Fraitag B, et al. (1999) Validation of a specific quality of life questionnaire in functional digestive disorders (FDDQL). Gut 44:527–533PubMedCentralPubMedCrossRef Chassany O, Marquis P, Scherrer B, Read NW, Finger T, Bergmann JF, Fraitag B, et al. (1999) Validation of a specific quality of life questionnaire in functional digestive disorders (FDDQL). Gut 44:527–533PubMedCentralPubMedCrossRef
17.
go back to reference Guillevin L, Ortonne JP (1983) Traitement de la sclérodermie. Ann Med Interne 34:754–765 Guillevin L, Ortonne JP (1983) Traitement de la sclérodermie. Ann Med Interne 34:754–765
18.
go back to reference Ruof J, Bruhlmann P, Michel BA, Stucki G (1999) Development and validation of a self-administered systemic sclerosis questionnaire (SySQ). Rheumatology 38:535–542PubMedCrossRef Ruof J, Bruhlmann P, Michel BA, Stucki G (1999) Development and validation of a self-administered systemic sclerosis questionnaire (SySQ). Rheumatology 38:535–542PubMedCrossRef
19.
go back to reference Clements PJ, Wong WK, Hurwitz EL, Furst DE, Mayes M, White B, et al. (2001) The Disability Index of the Health Assessment Questionnaire is a predictor and correlate of outcome in the high-dose versus low-dose penicillamine in systemic sclerosis trial. Arthritis Rheum 44:653–661PubMedCrossRef Clements PJ, Wong WK, Hurwitz EL, Furst DE, Mayes M, White B, et al. (2001) The Disability Index of the Health Assessment Questionnaire is a predictor and correlate of outcome in the high-dose versus low-dose penicillamine in systemic sclerosis trial. Arthritis Rheum 44:653–661PubMedCrossRef
20.
go back to reference Farge D, Marolleau JP, Zohar S, Marjanovic Z, Cabane J, Mounier N, et al. (2002) Autologous bone marrow transplantation in the treatment of refractory systemic sclerosis. Br J Haematol 119:729–739CrossRef Farge D, Marolleau JP, Zohar S, Marjanovic Z, Cabane J, Mounier N, et al. (2002) Autologous bone marrow transplantation in the treatment of refractory systemic sclerosis. Br J Haematol 119:729–739CrossRef
Metadata
Title
Validation of French version of the Scleroderma Health Assessment Questionnaire (SSc HAQ)
Authors
C. Georges
O. Chassany
L. Mouthon
K. Tiev
C. Toledano
O. Meyer
Z. Marjanovic
C. Heneggar
T. Papo
B. Crickx
D. Sereni
J. Cabane
D. Farge
Publication date
01-02-2005
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 1/2005
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-004-0942-3

Other articles of this Issue 1/2005

Clinical Rheumatology 1/2005 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.